Home LiteratureArticle Details
PMID: 22938502 Published · epublish English Journal Article

Myeloid cells in tumor inflammation.

Vascular cell ·Vol. 4 ·No. 1 ·2012-09-03 ·Pages 14

Schmid MC, Varner JA

Abstract

Bone marrow derived myeloid cells progressively accumulate in tumors, where they establish an inflammatory microenvironment that is favorable for tumor growth and spread. These cells are comprised primarily of monocytic and granulocytic myeloid derived suppressor cells (MDSCs) or tumor-associated macrophages (TAMs), which are generally associated with a poor clinical outcome. MDSCs and TAMs promote tumor progression by stimulating immunosuppression, neovascularization, metastasis and resistance to anti-cancer therapy. Strategies to target the tumor-promoting functions of myeloid cells could provide substantial therapeutic benefit to cancer patients.

Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Schmid Michael C
Moores UCSD Cancer Center, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093-0912, USA. jvarner@ucsd.edu.
Varner Judith A
References (83)
83 references, click to expand
  1. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.
    Cancer Cell. 2011 Apr 12;19(4):512-26 PMID: 21481792
  2. Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.
    Prostate. 2010 Mar 1;70(4):443-55 PMID: 19902470
  3. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.
    Nat Biotechnol. 2007 Aug;25(8):911-20 PMID: 17664940
  4. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.
    Blood. 2011 Aug 25;118(8):2254-65 PMID: 21734236
  5. Myeloid-derived suppressor cell heterogeneity and subset definition.
    Curr Opin Immunol. 2010 Apr;22(2):238-44 PMID: 20171075
  6. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas.
    J Pathol. 2000 Oct;192(2):150-8 PMID: 11004690
  7. Coordinated regulation of myeloid cells by tumours.
    Nat Rev Immunol. 2012 Mar 22;12(4):253-68 PMID: 22437938
  8. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice.
    Blood. 2008 Jun 15;111(12):5457-66 PMID: 18375791
  9. Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2.
    Cancer Res. 2008 May 1;68(9):3467-75 PMID: 18451175
  10. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.
    Cancer Cell. 2011 Jun 14;19(6):715-27 PMID: 21665146
  11. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance.
    Cancer Cell. 2012 Apr 17;21(4):488-503 PMID: 22516258
  12. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.
    Cell. 2004 Aug 6;118(3):285-96 PMID: 15294155
  13. Integrin alpha4beta1 promotes monocyte trafficking and angiogenesis in tumors.
    Cancer Res. 2006 Feb 15;66(4):2146-52 PMID: 16489015
  14. Urokinase and macrophages in tumour angiogenesis.
    Br J Cancer. 1995 Oct;72(4):818-23 PMID: 7547226
  15. Macrophage diversity enhances tumor progression and metastasis.
    Cell. 2010 Apr 2;141(1):39-51 PMID: 20371344
  16. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis.
    Nature. 2008 Dec 11;456(7223):814-8 PMID: 18997773
  17. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.
    Cancer Cell. 2009 Aug 4;16(2):91-102 PMID: 19647220
  18. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes.
    J Immunol. 2003 Aug 1;171(3):1232-9 PMID: 12874210
  19. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.
    Nat Med. 2007 Jul;13(7):828-35 PMID: 17603493
  20. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.
    Blood. 2008 Apr 15;111(8):4233-44 PMID: 18272812
  21. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.
    Cancer Cell. 2008 Jan;13(1):23-35 PMID: 18167337
  22. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion.
    Cancer Cell. 2008 Mar;13(3):206-20 PMID: 18328425
  23. Subsets of myeloid-derived suppressor cells in tumor-bearing mice.
    J Immunol. 2008 Oct 15;181(8):5791-802 PMID: 18832739
  24. Non-canonical alternatives: what a macrophage is 4.
    J Exp Med. 2012 Mar 12;209(3):427-31 PMID: 22412174
  25. The high level of RANTES in the ectopic milieu recruits macrophages and induces their tolerance in progression of endometriosis.
    J Mol Endocrinol. 2010 Nov;45(5):291-9 PMID: 20732991
  26. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.
    J Immunol. 2009 May 15;182(10):6562-8 PMID: 19414811
  27. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer.
    Blood. 2006 Jul 15;108(2):525-35 PMID: 16527895
  28. Integrin structure, allostery, and bidirectional signaling.
    Annu Rev Cell Dev Biol. 2005;21:381-410 PMID: 16212500
  29. Reactive oxygen species as intracellular messengers during cell growth and differentiation.
    Cell Physiol Biochem. 2001;11(4):173-86 PMID: 11509825
  30. The final steps of integrin activation: the end game.
    Nat Rev Mol Cell Biol. 2010 Apr;11(4):288-300 PMID: 20308986
  31. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth.
    PLoS One. 2009 Aug 10;4(8):e6562 PMID: 19668347
  32. Accessories to the crime: functions of cells recruited to the tumor microenvironment.
    Cancer Cell. 2012 Mar 20;21(3):309-22 PMID: 22439926
  33. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.
    Science. 2005 Jan 7;307(5706):58-62 PMID: 15637262
  34. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models.
    Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6742-7 PMID: 19346489
  35. NF-kappaB: linking inflammation and immunity to cancer development and progression.
    Nat Rev Immunol. 2005 Oct;5(10):749-59 PMID: 16175180
  36. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma.
    J Clin Pathol. 2004 Jun;57(6):630-6 PMID: 15166270
  37. Development of monocytes, macrophages, and dendritic cells.
    Science. 2010 Feb 5;327(5966):656-61 PMID: 20133564
  38. miR-511-3p modulates genetic programs of tumor-associated macrophages.
    Cell Rep. 2012 Feb 23;1(2):141-54 PMID: 22832163
  39. Macrophages and angiogenesis.
    J Leukoc Biol. 1994 Mar;55(3):410-22 PMID: 7509844
  40. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice.
    J Immunol. 2010 Jul 1;185(1):203-10 PMID: 20525890
  41. Macrophages: master regulators of inflammation and fibrosis.
    Semin Liver Dis. 2010 Aug;30(3):245-57 PMID: 20665377
  42. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
    Cancer Discov. 2011 Jun;1(1):54-67 PMID: 22039576
  43. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.
    J Clin Invest. 2004 Sep;114(5):623-33 PMID: 15343380
  44. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.
    Cancer Immunol Immunother. 2009 Jan;58(1):49-59 PMID: 18446337
  45. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.
    Genes Dev. 2011 Dec 1;25(23):2465-79 PMID: 22156207
  46. Integrins in angiogenesis and lymphangiogenesis.
    Nat Rev Cancer. 2008 Aug;8(8):604-17 PMID: 18497750
  47. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.
    J Exp Med. 2010 Oct 25;207(11):2439-53 PMID: 20876310
  48. Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth.
    Cancer Res. 2011 Nov 15;71(22):6965-75 PMID: 21948958
  49. Differential macrophage programming in the tumor microenvironment.
    Trends Immunol. 2012 Mar;33(3):119-26 PMID: 22277903
  50. Protective and pathogenic functions of macrophage subsets.
    Nat Rev Immunol. 2011 Oct 14;11(11):723-37 PMID: 21997792
  51. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
    J Clin Oncol. 2007 Jun 20;25(18):2546-53 PMID: 17577033
  52. Reconstruction of integrin activation.
    Blood. 2012 Jan 5;119(1):26-33 PMID: 21921044
  53. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.
    Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):721s-726s PMID: 17255300
  54. Recreation of the terminal events in physiological integrin activation.
    J Cell Biol. 2010 Jan 11;188(1):157-73 PMID: 20048261
  55. Alternative activation of macrophages: mechanism and functions.
    Immunity. 2010 May 28;32(5):593-604 PMID: 20510870
  56. Immune cell migration in inflammation: present and future therapeutic targets.
    Nat Immunol. 2005 Dec;6(12):1182-90 PMID: 16369557
  57. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF.
    Cancer Cell. 2011 Jan 18;19(1):31-44 PMID: 21215706
  58. Cancer-related inflammation.
    Nature. 2008 Jul 24;454(7203):436-44 PMID: 18650914
  59. Macrophages regulate the angiogenic switch in a mouse model of breast cancer.
    Cancer Res. 2006 Dec 1;66(23):11238-46 PMID: 17114237
  60. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells.
    J Immunol. 2009 May 1;182(9):5693-701 PMID: 19380816
  61. Bv8 regulates myeloid-cell-dependent tumour angiogenesis.
    Nature. 2007 Dec 6;450(7171):825-31 PMID: 18064003
  62. Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain.
    J Biol Chem. 1996 May 10;271(19):11067-75 PMID: 8626649
  63. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
    J Exp Med. 2003 Dec 1;198(11):1741-52 PMID: 14657224
  64. Myeloid-derived suppressor cells: linking inflammation and cancer.
    J Immunol. 2009 Apr 15;182(8):4499-506 PMID: 19342621
  65. Integrins in cancer: biological implications and therapeutic opportunities.
    Nat Rev Cancer. 2010 Jan;10(1):9-22 PMID: 20029421
  66. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice.
    J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42 PMID: 12165638
  67. Fine-tuning leukocyte responses: towards a chemokine 'interactome'.
    Trends Immunol. 2006 Jun;27(6):268-73 PMID: 16678487
  68. Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling.
    J Biol Chem. 2012 Jun 1;287(23):19574-84 PMID: 22528488
  69. Getting to the site of inflammation: the leukocyte adhesion cascade updated.
    Nat Rev Immunol. 2007 Sep;7(9):678-89 PMID: 17717539
  70. Blocking the alpha 4 integrin-paxillin interaction selectively impairs mononuclear leukocyte recruitment to an inflammatory site.
    J Clin Invest. 2006 Mar;116(3):715-23 PMID: 16470243
  71. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.
    J Clin Invest. 2006 Oct;116(10):2777-90 PMID: 17016559
  72. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.
    J Immunol. 2001 Jan 1;166(1):678-89 PMID: 11123353
  73. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.
    Blood. 2000 Dec 1;96(12):3838-46 PMID: 11090068
  74. Talin 1 and paxillin facilitate distinct steps in rapid VLA-4-mediated adhesion strengthening to vascular cell adhesion molecule 1.
    J Biol Chem. 2007 Aug 31;282(35):25338-48 PMID: 17597073
  75. Integrins in the immune system.
    Adv Immunol. 1999;72:325-80 PMID: 10361579
  76. Arginase: an emerging key player in the mammalian immune system.
    Br J Pharmacol. 2009 Oct;158(3):638-51 PMID: 19764983
  77. Integrins in tumor angiogenesis and lymphangiogenesis.
    Methods Mol Biol. 2012;757:471-86 PMID: 21909928
  78. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression.
    Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2640-5 PMID: 18268320
  79. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.
    Nat Immunol. 2010 Oct;11(10):889-96 PMID: 20856220
  80. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.
    Cancer Res. 2006 Jul 1;66(13):6807-15 PMID: 16818658
  81. Immunity, inflammation, and cancer.
    Cell. 2010 Mar 19;140(6):883-99 PMID: 20303878
  82. Macrophages, innate immunity and cancer: balance, tolerance, and diversity.
    Curr Opin Immunol. 2010 Apr;22(2):231-7 PMID: 20144856
  83. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
    Gastroenterology. 2008 Jul;135(1):234-43 PMID: 18485901
Article Info
Journal
Vascular cell
Abbr.
Vasc Cell
ISSN
2045-824X
DOI
10.1186/2045-824X-4-14
Email
jvarner@ucsd.edu
Published
2012-09-03
Epub
2012-00-03
Pages
14
Language
English
Region
England
NLM ID
101553155
PMCID
PMC3479419
Grants
NCI NIH HHS · R01 CA167426 · United States
External Links
PubMed source DOI: 10.1186/2045-824X-4-14 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2